ArticleEffects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers
References (59)
- et al.
Neuroendocrine and behavioral effects of m-chlorophenyl-piperazine administration in rhesus monkeys
Life Sci
(1984) - et al.
Functional interrelationship of serotonin and norepinephrine: Cortisol responses to mCPP and DMI in patients with panic disorder, patients with depression, and normal control subjects
Psychiatry Res
(1992) - et al.
Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia
Biol Psychiatry
(1993) Minireview. MK-212: A serotonin-like agonist in the CNS
Gen Pharmacol
(1979)- et al.
Pharmacological differentiation of the central 5-hydroxytryptamine-like actions of MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine), pmethoxyamphetamine and fenfluramine in an in vivo model system
Eur J Pharmacol
(1978) - et al.
m-CPP: A tool for studying behavioral responses associated with 5-HT1c receptors
Trends Pharmacol Sci
(1990) - et al.
Binding of arylpiperazines to 5-HT3 serotonin receptors: Results of a structure-affinity study
Eur J Pharmacol
(1989) - et al.
Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat: Evidence for opposing roles of 5-HT2 and 5-HT1A receptors
Neuropharmacology
(1986) - et al.
Effects of MCPP on receptor binding and brain metabolism of monoamines in rats
Neurochem Int
(1981) - et al.
The mCPP challenge test in schizophrenia: Hormonal and behavioral responses
Biol Psychiatry
(1991)
Serotonin function in schizophrenia: Effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects
Psychiatry Res
m-Chlorophenylpiperazine as a probe of serotonin receptors: A review
Biol Psychiatry
Anxiogenic-like effects of m-CPP and TFMPP in animal models are opposed by 5-HT1c receptor antagonists
Eur J Pharmacol
Neuroendocrine responses in chronic schizophrenia: Evidence for a serotonergic dysfunction
Schizophr Res
Stimulation of serum cortisol and prolactin secretion in man by MK-212, a centrally active serotonin agonist
Biol Psychiatry
Effect of pindolol pretreatment on mCPP-induced plasma cortisol and prolactin responses in normal men
Psychiatry Res
Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics
Biol Psychiatry
Effects of naloxone on the secretion of prolactin and corticosterone induced by 5-hydroxytryptophan and a serotonergic agonist, mCPP
Life Sci
Clinical studies of 5-HT function using i.v. l-tryptophan
Prog Neuropsychopharmacol Biol Psychiatry
Effect of MK-212, a centrally acting serotonin agonist, on prolactin, cortisol and body temperature in schizophrenia
Biol Psychiatry
Effects of ritanserin on the behavioral, neuroendocrine, and cardio-vascular responses to m-CPP in healthy human subjects
Psychiatry Res
Use of placebo controlled models in neuroendocrine challenge studies in psychiatric research
Psychiatry Res
Minireview. Neuroendocrine probes of serotonergic function: A critical review
Life Sci
Serotonin 2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients
J Neural Transm
Different serotonin receptors mediate blood-pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats
J Pharmacol Exp Ther
Neurotransmitter receptors in frontal cortex of schizophrenics
Arch Gen Psychiatry
The role of serotonin in schizophrenia
Schizophr Bull
Effects of serotonin antagonism in schizophrenia: A pilot study with setoperone
Psychopharmacology
Cited by (19)
Serotonin and schizophrenia
2020, Handbook of Behavioral NeuroscienceCitation Excerpt :m-CPP increases anxiety, body temperature, and plasma levels of prolactin, cortisol, GH, and ACTH, but does not provoke psychotic symptoms in healthy human volunteers (Breier, 1995). Schizophrenia patients show either blunted (Iqbal et al., 1991; Maes & Meltzer, 1996) or normal prolactin responses to m-CPP (Kahn et al., 1992; Krystal et al., 1993). Moreover, m-CPP has been reported to exacerbate (Abi-Saab et al., 2002; Iqbal et al., 1991; Krystal et al., 1993), reduce (Kahn et al., 1992), or have no effect on psychotic symptoms (Breier, Kirkpatrick, & Buchanan, 1993; Koreen, Lieberman, Alvir, & Chakos, 1997; Owen et al., 1993).
Decreased serotonin<inf>2C</inf> receptor responses in male patients with schizophrenia
2015, Psychiatry ResearchCitation Excerpt :We found no relation between the temperature responses and body mass index (data not presented). The decreased behavioral response to MK-212 in patients with SCH is in contrast to our prior report in a small sample with MK-212 (Lee et al., 1992), and with m-CPP using 0.5 mg/kg (Maes and Meltzer, 1996), which did not show significant difference in behavioral responses between groups. The main reasons may likely to be sample size, the greater specificity of MK-212 for 5-HT2C receptors than m-CPP, and the dosage of m-CPP used.
Rethinking responsibility in offenders with acquired paedophilia: Punishment or treatment?
2015, International Journal of Law and PsychiatryCitation Excerpt :Many factors have been postulated to indicate that individuals with paedophilia may have neurodevelopmental or neurochemical impairments (De Ridder, Langguth, Plazier, & Menovsky, 2009). Neurochemical findings show that individuals with developmental paedophilia may have a serotonergic disturbance, most likely caused by the decreased activity of the presynaptic serotonergic neurons and hypersensitivity of the serotonin 2 postsynaptic receptors (Maes & Meltzer, 1996; Maes et al., 2001). Previous reports (Moller & Bier-Weiss, 1995) have shown that disorders in serotonin metabolism and increased sympathoadrenal system activity are related to aggression or violence and impulse control disorder.
Serotonin and Schizophrenia
2010, Handbook of Behavioral Neuroscience6 5-HT<inf>2C</inf> Ligands: Recent Progress
2008, Progress in Medicinal ChemistryCitation Excerpt :One potential issue for this approach to the treatment of schizophrenia is the observation of mixed effects with the non-selective 5-HT2C receptor agonist m-chlorophenylpiperazine (mCPP) (8) in clinical studies on schizophrenics. While Kahn et al.[110] reported that low oral doses of mCPP decreased psychotic symptoms, others reported that either it caused only non-specific effects, such as feeling calm [111, 112], or that it mildly increased positive symptoms without effect on negative symptoms [113, 114]. The exacerbating action of mCPP on positive symptoms was reportedly reversed by pretreatment with the 5-HT2A and 5-HT2C receptor antagonist, ritanserin [115].